Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05858164




Registration number
NCT05858164
Ethics application status
Date submitted
5/05/2023
Date registered
15/05/2023
Date last updated
26/06/2024

Titles & IDs
Public title
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Scientific title
An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKai) BAY 2862789 in Participants With Advanced Solid Tumors
Secondary ID [1] 0 0
2024-510998-26-00
Secondary ID [2] 0 0
22231
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors 0 0
Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BAY2862789

Experimental: Dose Escalation - Participants will take BAY2862789 oral doses.

Experimental: Dose Expansion - Participants will take BAY2862789 oral doses. Dose Expansion starts after Dose Escalation.


Treatment: Drugs: BAY2862789
Oral administration, solution or tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The number and severity of treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
Up to 90 days after the last administration of the study treatment
Primary outcome [2] 0 0
Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level in the Dose Escalation part of the study
Timepoint [2] 0 0
Up to 21 days after the first administration of the study treatment
Primary outcome [3] 0 0
Recommended phase 2 dose (RP2D)
Timepoint [3] 0 0
Up to 2 years
Primary outcome [4] 0 0
Maximum concentration (Cmax) BAY2862789 after single-dose
Timepoint [4] 0 0
Pre-dose and 1-4 hours post-dose on Day 1 in each cycle from Cycle 2
Primary outcome [5] 0 0
Maximum concentration (Cmax) BAY2862789 after multiple-dose
Timepoint [5] 0 0
Pre-dose and up to 24 hours after Day 16 in Cycle 1
Primary outcome [6] 0 0
Area under the curve (AUC) BAY2862789 after single-dose
Timepoint [6] 0 0
Pre-dose and 1-4 hours post-dose on Day 1 in each cycle from Cycle 2
Primary outcome [7] 0 0
Area under the curve (AUC) BAY2862789 after multiple-dose
Timepoint [7] 0 0
Pre-dose and up to 24 hours after Day 16 in Cycle 1
Secondary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Up to 2 years
Secondary outcome [2] 0 0
Disease control rate (DCR)
Timepoint [2] 0 0
Up to 2 years
Secondary outcome [3] 0 0
Duration of response (DOR)
Timepoint [3] 0 0
Up to 2 years
Secondary outcome [4] 0 0
Progression-free survival (PFS) at 6 months
Timepoint [4] 0 0
Up to 6 months
Secondary outcome [5] 0 0
Overall survival (OS) at 12 months
Timepoint [5] 0 0
Up to 12 months
Secondary outcome [6] 0 0
Activation of effector T memory cells
Timepoint [6] 0 0
Up to 2 years
Secondary outcome [7] 0 0
Ex vivo stimulated short-term activation of Interleukin 2 (IL2) and interferon-gamma
Timepoint [7] 0 0
Up to 2 years

Eligibility
Key inclusion criteria
* Capable of giving signed informed consent
* Be =18 years of age on day of signing informed consent.
* Have measurable disease per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) as assessed by the local site investigator.
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
* Participants with a histologically confirmed diagnosis of a solid tumor that have exhausted available treatments known to be beneficial for this tumor type or for whom these treatments are not acceptable and for whom this trial is a reasonable option for them, will be enrolled onto this study. Appropriate molecular profiling of tumors should have been performed according to local national guidelines prior to trial entry. Specifications for the different parts of the study are below:

-- Dose escalation: All solid cancers, except primary central nervous system cancers.
* Non-small cell lung cancer (NSCLC): Participants with NSCLC must have received an approved PD1/L-1 containing regimen and platinum chemotherapy, as applicable. Participants with known targetable genomic aberrations should have received available targeted drugs deemed appropriate by the investigator. (apart from NSCLC participants with endothelial growth factor receptor [EGFR] or alkaline phosphatase [ALK] mutations who will not be eligible).
* Provision of archival tumor sample at baseline is mandatory for all participants in escalation, and expansion cohorts.
* Participants recruited to expansion cohorts must be willing to undergo mandatory paired biopsies of tumor (re and on treatment).
* Have adequate organ function.
* Agree to use contraception during the treatment period and for at least 6 months after the last dose of study treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Had an allogeneic tissue/solid organ transplant.
* Previous therapy with a diacylglycerol kinase (DGK) inhibitor
* Has received a prior therapeutic regimen containing an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-programmed cell death 1 ligand 2 (anti PD-L2) agent or an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX 40, CD137) and was discontinued from that treatment regimen due to a Grade 3 or higher immune related adverse event (irAE) or any toxicity that was life-threatening.
* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 half-lives, whatever is shorter, prior to treatment. Growth factor treatments such as granulocyte colony-stimulating factor (G-CSF) must have been discontinued 4 weeks prior to entering the study.
* Participants must have recovered from previous radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
* Participants cannot have had a blood transfusion within 2 weeks of starting therapy.
* Has received a live vaccine within 30 days prior to the first dose of study drug.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Participants with new brain metastases on screening brain magnetic resonance imaging/computed tomography (MRI/CT).
* Primary central nervous system malignancy or presence of leptomeningeal disease.
* Participants with gastrointestinal conditions that may compromise oral absorption such as short bowel syndrome or active tumor-related bowel obstruction with ongoing symptoms compromising absorption over last 6 months.
* Has an active autoimmune disease including inflammatory bowel disease that has required systemic treatment in past 2 years.
* Current pneumonitis / interstitial lung disease.
* Has an active infection requiring systemic therapy.

Study design
Purpose of the study
Other
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Factorial
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/08/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
2/03/2027
Actual
Sample size
Target
102
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
The Kinghorn Cancer Centre - Medical Oncology Department - Darlinghurst
Recruitment hospital [2] 0 0
Princess Alexandra Hospital Australia - Woollongabba
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
4106 - Woollongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Mississippi
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Utah
Country [8] 0 0
China
State/province [8] 0 0
Hubei
Country [9] 0 0
China
State/province [9] 0 0
Jilin
Country [10] 0 0
Israel
State/province [10] 0 0
Jerusalem
Country [11] 0 0
Israel
State/province [11] 0 0
Tel Aviv
Country [12] 0 0
Japan
State/province [12] 0 0
Kashiwa
Country [13] 0 0
Korea, Republic of
State/province [13] 0 0
Chungcheongbugdo
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Seoul Teugbyeolsi
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Jinju-si
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Spain
State/province [17] 0 0
Barcelona
Country [18] 0 0
Spain
State/province [18] 0 0
Malaga

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Researchers are looking for a better way to treat people who have advanced solid tumors including a specific kind of lung cancer (non-small cell lung cancer, NSCLC).

Advanced solid tumors are types of cancer that have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments.

BAY2862789 works by blocking an enzyme in T-cells, thereby activating them. T-cells are a type of immune cell that are known to have an anti-cancer effect.

The main purpose of this first-in-human study is to learn:

* how safe different doses of BAY2862789 are,
* the degree to which medical problems caused by BAY2862789 can be tolerated (also called tolerability),
* what maximum amount (dose) can be given, and
* how BAY2862789 moves into, through and out of the body.

To answer this, the researchers will look at:

* the number and severity of medical problems participants have after taking BAY2862789 for each dose level. These medical problems are also referred to as adverse events. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important.
* the (average) total level of BAY2862789 in the blood (also called AUC) after intake of single and multiple doses.
* the (average) highest level of BAY2862789 in the blood (also called Cmax) after intake of single and multiple doses.

Doctors and their team keep track of all medical problems that participants have during the study, even if they do not think the medical problem might be related to the study treatment.

In addition, the researchers want to know if and how the participants' tumors change after taking BAY2862789.

The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose that can be given in the second part of the study. For this, each participant will receive one of the increasing doses of BAY2862789.

All participants in the second part of the study, called dose expansion, will receive the most appropriate dose identified from the first part of the study, as tablet by mouth. Participants in both parts of the study, will take the study treatment until their tumor gets worse (also known as 'disease progression'), until they have medical problems, until they leave the study, or until the study is terminated.

Each participant will be in the study for several months, including a test (screening) phase of up to 28 days, few months of treatment depending on the participant's benefit, and a follow up phase after the end of treatment. The following approximate numbers of visits to the study site are planned: two during the screening phase, six in the first treatment month, one to three per month in the following periods.

During the study, the study team will:

* take blood and urine samples
* do physical examinations
* check vital signs such as blood pressure, heart rate, body temperature
* examine heart health using ECG (electrocardiogram)
* check cancer status using CT (computed tomography) or MRI (magnetic resonance imaging) and, if needed, bone scans
* take tumor samples (if required)
* pregnancy test

The treatment period ends with a visit no later than 7 days after the last BAY2862789 dose. The study doctors and their team will check the participants' health and any changes in cancer about 30 and 90 days after the last dose and every 12 weeks thereafter. This follow-up period ends if the cancer worsens, if a new anti-cancer treatment is started, or until the participant leaves the study. In addition, the study doctors and their team will contact the participant every 12 weeks to learn about the participant's survival. This ends no later than 12 months after the last participant started treatment or by the end of the study, whichever comes first.

If the study participant benefits from treatment, continuation of treatment with BAY2862789 beyond the duration of this study might be possible.
Trial website
https://clinicaltrials.gov/study/NCT05858164
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Bayer Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
(+)1-888-84 22937
Fax 0 0
Email 0 0
clinical-trials-contact@bayer.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05858164